AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 5 cutMore cutting
Market overview
Fundamentals Jun 16- 52-wk high
- $27.00
- 52-wk low
- $9.83
- Mkt cap
- $1.44B
- Fwd P/E
- 25.4x
- Beta
- -0.11
- P/S
- 12.6x
- P/B
- 49.0x
- Profit margin
- -118.7%
- Op margin
- -57.4%
- ROE
- -190.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about KALV filings
Are insiders buying or selling Kalvista Pharmaceuticals Inc (KALV) stock?
Neither. Kalvista Pharmaceuticals Inc (KALV) insiders filed no open-market purchases or sales in the 90 days to Oct 12, 2026, according to SEC Form 4 filings.
Which members of Congress have traded KALV recently?
None. No member of Congress disclosed a KALV trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this KALV smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (3)
- P7
Point72
$43.0M
sold
- MI
Millennium
$38.5M
sold
- BO
Bank of America
$11.2M
sold
What insiders are doing
How top traders are positioned
No tracked top-trader positions in KALV right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 14.3% below what analysts expected.
Last report
May 15, 2026
Period ending
Apr 30, 2026
Earnings per share
-$0.38 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | May 15, 2026 | -$0.43 / -$0.38Alpha Vantage | -14.27% miss | Unavailable | Unavailable |
| Jan 31, 2026 | Mar 24, 2026 | $0.94 / -$0.53Alpha Vantage | +$1.47 beat | Unavailable | Unavailable |
| Oct 31, 2025 | Nov 10, 2025 | -$0.92 / -$0.96Alpha Vantage | +4.17% beat | Unavailable | Unavailable |
| Jul 31, 2025 | Sep 11, 2025 | -$1.12 / -$0.90Alpha Vantage | -24.44% miss | Unavailable | Unavailable |
| Apr 30, 2025 | Jul 10, 2025 | -$0.99 / -$0.81Alpha Vantage | -22.22% miss | Unavailable | Unavailable |
| Jan 31, 2025 | Mar 12, 2025 | -$0.92 / -$0.87Alpha Vantage | -5.75% miss | Unavailable | Unavailable |
| Oct 31, 2024 | Dec 5, 2024 | -$0.91 / -$0.91Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Jul 31, 2024 | Sep 5, 2024 | -$0.87 / -$0.91Alpha Vantage | +4.40% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
What the street expects next
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -118.7%
- Forward P/E
- 25.45
- Market cap
- $1.4B
Valuation
- P/S12.56
- P/B49.03
Quality
- Operating margin-57.4%
- ROE-190.2%
- ROA-61.0%
Growth
- Beta-0.11
Technicals
Price structure
Market data unavailable.